查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108332

眼科保健市場分析及預測（至2035年）：類型、產品、技術、應用、形式、設備、最終用戶、功能、解決方案

Ophthalmic Medicine Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Form, Device, End User, Functionality, Solutions
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球眼科保健市場預計將從2025年的396億美元成長到2035年的902億美元，CAGR為8.6%。人口老化、糖尿病相關眼部併發症、青光眼、視網膜疾病和乾眼症等疾病的診斷，推動了治療需求的成長，進而促進了全球眼科保健市場的持續擴張。美國食品藥物管理局（FDA）整體眼科藥品實施廣泛的監管措施，而美國國家眼科研究所（NEI）的報告顯示，數百萬美國人患有嚴重的視力障礙和眼科疾病，這表明潛在患者群體龐大。在全球範圍內，市場需求正轉向生物製劑、生物相似藥、緩釋製劑以及視網膜疾病的專科治療。醫療保健支出的增加、眼科檢查的改進、臨床研發管線的拓展以及先進視力保健服務的普及，都進一步推動了市場成長。

該市場由處方藥、非處方藥、生物製劑、生物相似藥和其他眼科專用藥品組成。處方藥繼續發揮核心作用，尤其是在治療青光眼、視網膜疾病和眼部發炎等慢性疾病方面；而非處方藥則用於緩解乾眼症和輕度刺激等常見症狀。由於其標靶作用機制和臨床療效，生物製劑在視網膜血管和發炎性疾病的治療中日益重要。生物相似藥透過促進競爭和減輕患者的經濟負擔，擴大了高成本生物製劑的可及性。人口老化、糖尿病盛行率上升、眼科疾病診斷率增加以及創新療法的持續研發，都為該領域的市場前景提供了支持。

市場區隔
類型 處方藥、非處方藥、生物製劑、生物相似藥、其他
產品 眼藥水、軟膏、膠囊/錠劑、注射、凝膠、植入物、其他
技術 基因療法、幹細胞療法、奈米技術、藥物傳輸系統、其他
用途 青光眼、乾眼症、視網膜疾病、過敏性結膜炎、葡萄膜炎、其他
形式 液體、固體、半固體、其他
裝置 人工水晶體、隱形眼鏡、眼科雷射、診斷設備、其他
最終用戶 醫院、眼科診所、零售藥局、網路藥局、其他
功能 抗發炎、抗感染、青光眼治療、抗過敏、其他
解決方案 視力保健、外科手術解決方案、診斷解決方案、治療解決方案、其他

技術領域涵蓋基因療法、幹細胞療法、奈米技術、藥物遞送系統及其他新興平台。基因療法透過針對潛在的基因異常，治療遺傳性視網膜疾病，正日益受到關注；而幹細胞療法則目的是修復或替換受損的眼部組織。奈米技術有助於提高藥物穩定性、生物利用度和標靶遞送能力。同時，包括緩釋植入和眼內植入物在內的先進藥物遞送系統，目的是減少給藥頻率並提高治療依從性。這些技術透過克服傳統眼藥水和注射劑的局限性，改變眼科治療。生物技術、臨床研究、精準醫療領域投資的不斷成長，以及對永續治療方案的需求，都為該領域的發展前景提供了支持。

區域概覽

北美憑藉其先進的醫療基礎設施、高診斷率和治療率以及強大的製藥和生物技術能力，在眼科醫療市場中保持主導地位。美國是該地區的主要需求國，因為其老齡化黃斑部病變、糖尿病視網膜病變、青光眼和乾眼症的盛行率極高。強大的專科醫生網路、先進的眼科手術中心、完善的醫保償付體係以及高額的醫療支出推動市場滲透。該地區還受益於廣泛的研發活動、風險投資以及對創新療法的監管支持。其完善的臨床試驗基礎設施以及生物製劑、生物相似藥、基因療法和先進藥物遞送技術的快速發展，預計將繼續保持其商業性重要性。

亞太地區人口基數龐大，糖尿病和老齡化性眼科疾病患病率不斷上升，醫療保健服務可及性日益提高，以及人們對保護視力重要性的認知不斷增強，因此蘊藏著巨大的成長機會。中國、日本、印度、韓國和其他新興經濟體加強藥品生產和眼科醫療基礎建設，國內外企業也不斷擴大其生產、分銷和研發能力。政府的醫療保健政策、擴大的保險覆蓋範圍、都市化以及對專科醫院的投資，都提高了眼科治療的可及性。創新生物製劑、價格合理的生物相似藥和先進給藥系統的日益普及，預計將拓寬治療選擇。此外，臨床研究的拓展和本地生產能力的提升，可望為該地區的長期市場發展提供支持。

主要趨勢和促進因素

過渡到精準且長效的眼科治療

眼科醫療市場正日益轉向長效、標靶和精準的醫療療法，以期在改善臨床療效的同時減少治療頻率。生物製劑和生物相似藥在視網膜疾病的治療中日益重要，而緩釋植入、注射劑、奈米技術和新型眼內給藥平台也研發中，以克服傳統眼藥水吸收受限和停留時間短的缺點。基因療法也推動某些遺傳性視網膜疾病的治療。這種轉變反映了人們對以患者為中心的治療模式、提高遵守用藥、獲得持續療效以及能夠應對複雜、慢性且威脅視力的疾病的解決方案的日益成長的需求。

全球範圍內，威脅視力的眼科疾病負擔日益加重。

全球眼科疾病負擔日益加重是市場成長的主要驅動力，人口老化、糖尿病盛行率上升、預期壽命延長以及疾病檢測能力的提高進一步推動了該成長。老齡化黃斑部病變、糖尿病視網膜病變、青光眼和乾眼症等疾病持續引發了對藥物治療和長期疾病管理的需求。由於人們對眼部健康的認知不斷提高，篩檢計畫的擴展，眼病診斷率不斷上升；醫療基礎設施的改善也使更多患者能夠獲得專科醫生的治療。同時，製藥領域的創新透過生物製劑、生物相似藥、基因療法和先進的藥物遞送系統等手段拓寬了治療選擇，為市場擴張創造了更多機會。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 處方藥
    • 非處方藥
    • 生物製劑
    • 生物相似藥
    • 其他
  • 市場規模及預測：依產品分類
    • 眼藥水
    • 軟膏
    • 膠囊和片劑
    • 注射藥物
    • 凝膠
    • 植入
    • 其他
  • 市場規模及預測：依技術分類
    • 基因治療
    • 幹細胞療法
    • 奈米科技
    • 藥物輸送系統
    • 其他
  • 市場規模及預測：依應用領域分類
    • 青光眼
    • 乾眼症
    • 視網膜疾病
    • 過敏性結膜炎
    • 葡萄膜炎
    • 其他
  • 市場規模及預測：依類型
    • 液體
    • 固體
    • 半固體
    • 其他
  • 市場規模及預測：依設備分類
    • 人工水晶體
    • 隱形眼鏡
    • 眼科雷射
    • 診斷設備
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 眼科診所
    • 零售藥房
    • 網路藥房
    • 其他
  • 市場規模及預測：依功能分類
    • 抗發炎
    • 抗感染
    • 青光眼治療
    • 抗過敏
    • 其他
  • 市場規模及預測：依解決方案分類
    • 視力保健
    • 外科解決方案
    • 診斷解決方案
    • 治療方案
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Novartis
  • Roche
  • Allergan
  • Bausch Health
  • Alcon
  • Johnson and Johnson
  • Bayer
  • Pfizer
  • Santen Pharmaceutical
  • Regeneron Pharmaceuticals
  • Sun Pharmaceutical
  • Aerie Pharmaceuticals
  • Otsuka Pharmaceutical
  • Teva Pharmaceutical
  • AbbVie
  • Sanofi
  • GlaxoSmithKline
  • AstraZeneca
  • Merck
  • Eli Lilly

第9章 關於我們

簡介目錄
Product Code: GIS34836

The global ophthalmic medicine market is projected to grow from $39.6 billion in 2025 to $90.2 billion by 2035, at a compound annual growth rate (CAGR) of 8.6%. The global ophthalmic drugs market continues to expand as aging populations, diabetes-related eye complications, and increasing diagnosis of glaucoma, retinal diseases, and dry-eye conditions strengthen treatment demand. The U.S. Food and Drug Administration maintains extensive regulatory activity across ophthalmic drug products, while the National Eye Institute reports that millions of Americans are affected by major vision and eye conditions, supporting a substantial addressable patient base. Globally, demand is shifting toward biologics, biosimilars, sustained-release formulations, and specialized therapies for retinal disorders. Market growth is further supported by rising healthcare expenditure, improved ophthalmic screening, expanding clinical pipelines, and increasing access to advanced vision-care services.

The market is structured around prescription drugs, over-the-counter drugs, biologics, biosimilars, and other specialized ophthalmic medicines. Prescription drugs remain central to chronic disease management, particularly glaucoma, retinal disorders, and ocular inflammation, while over-the-counter products address high-volume conditions such as dry eye and minor irritation. Biologics are increasingly important for retinal vascular diseases and inflammatory disorders because of their targeted mechanisms and clinical efficacy. Biosimilars are expanding access to high-cost biologic treatments by supporting price competition and broader patient affordability. The segment outlook remains favorable, supported by aging populations, rising diabetes prevalence, increasing ophthalmic disease diagnosis, and continued development of innovative therapies.

Market Segmentation
TypePrescription Drugs, Over-the-Counter Drugs, Biologics, Biosimilars, Others
ProductEye Drops, Ointments, Capsules and Tablets, Injectables, Gels, Implants, Others
TechnologyGene Therapy, Stem Cell Therapy, Nanotechnology, Drug Delivery Systems, Others
ApplicationGlaucoma, Dry Eye Syndrome, Retinal Disorders, Allergic Conjunctivitis, Uveitis, Others
FormLiquid, Solid, Semi-Solid, Others
DeviceIntraocular Lenses, Contact Lenses, Ophthalmic Lasers, Diagnostic Devices, Others
End UserHospitals, Ophthalmic Clinics, Retail Pharmacies, Online Pharmacies, Others
FunctionalityAnti-inflammatory, Anti-infective, Anti-glaucoma, Anti-allergy, Others
SolutionsVision Care, Surgical Solutions, Diagnostic Solutions, Therapeutic Solutions, Others

Technology segmentation includes gene therapy, stem cell therapy, nanotechnology, drug delivery systems, and other emerging platforms. Gene therapy is gaining attention for inherited retinal disorders by targeting underlying genetic abnormalities, while stem cell approaches seek to restore or replace damaged ocular tissues. Nanotechnology supports improved drug stability, bioavailability, and targeted delivery, whereas advanced drug delivery systems, including sustained-release implants and ocular inserts, aim to reduce dosing frequency and improve treatment adherence. These technologies are transforming ophthalmic therapeutics by addressing limitations associated with conventional eye drops and injections. Growth prospects are supported by biotechnology investment, clinical research, precision medicine, and increasing demand for durable treatment solutions.

Geographical Overview

North America maintains a leading position in the ophthalmic medicine market, supported by advanced healthcare infrastructure, high diagnosis and treatment rates, and substantial pharmaceutical and biotechnology capabilities. The United States represents the region's primary demand base, with significant prevalence of age-related macular degeneration, diabetic retinopathy, glaucoma, and dry-eye disease. Strong specialist networks, advanced ophthalmic surgical centers, reimbursement mechanisms, and high healthcare expenditure reinforce market penetration. The region also benefits from extensive research and development activity, venture investment, and regulatory support for innovative therapies. Established clinical trial infrastructure and rapid adoption of biologics, biosimilars, gene therapies, and advanced drug delivery technologies are expected to sustain its commercial importance.

Asia-Pacific presents substantial expansion opportunities due to its large population base, increasing prevalence of diabetes and age-related eye disorders, improving healthcare access, and growing awareness of vision preservation. China, Japan, India, South Korea, and other emerging economies are strengthening pharmaceutical manufacturing and ophthalmic care infrastructure, while domestic and multinational companies continue expanding production, distribution, and research capabilities. Government healthcare initiatives, rising insurance coverage, urbanization, and investments in specialty hospitals are improving access to ophthalmic treatments. Increasing adoption of innovative biologics, affordable biosimilars, and advanced delivery systems is expected to broaden treatment availability, while expanding clinical research and local manufacturing capacity will support long-term regional market development.

Key Trends and Drivers

The Shift Toward Precision and Long-Acting Eye Therapies:

The ophthalmic medicine market is increasingly shifting toward long-acting, targeted, and precision-based therapies that improve clinical outcomes while reducing treatment frequency. Biologics and biosimilars are gaining importance in retinal disease management, while sustained-release implants, injectable formulations, nanotechnology, and novel ocular delivery platforms are being developed to overcome the limited absorption and short residence time associated with conventional eye drops. Gene therapies are also advancing the therapeutic landscape for selected inherited retinal disorders. This transition reflects growing demand for patient-centric treatment models, improved adherence, durable therapeutic effects, and solutions capable of addressing complex chronic and vision-threatening conditions.

Rising Global Burden of Vision-Threatening Eye Disorders:

The rising global burden of ophthalmic disorders is a primary market growth driver, reinforced by population aging, increasing diabetes prevalence, longer life expectancy, and improved disease detection. Age-related macular degeneration, diabetic retinopathy, glaucoma, and dry-eye disease are generating sustained demand for pharmacological intervention and long-term disease management. Greater awareness of eye health and expanded screening programs are increasing diagnosis rates, while healthcare infrastructure improvements are enabling more patients to access specialist treatment. In parallel, pharmaceutical innovation is broadening therapeutic options through biologics, biosimilars, gene-based treatments, and advanced drug delivery systems, creating additional opportunities for market expansion.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by Form
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Prescription Drugs
    • 4.1.2 Over-the-Counter Drugs
    • 4.1.3 Biologics
    • 4.1.4 Biosimilars
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Eye Drops
    • 4.2.2 Ointments
    • 4.2.3 Capsules and Tablets
    • 4.2.4 Injectables
    • 4.2.5 Gels
    • 4.2.6 Implants
    • 4.2.7 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Gene Therapy
    • 4.3.2 Stem Cell Therapy
    • 4.3.3 Nanotechnology
    • 4.3.4 Drug Delivery Systems
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Glaucoma
    • 4.4.2 Dry Eye Syndrome
    • 4.4.3 Retinal Disorders
    • 4.4.4 Allergic Conjunctivitis
    • 4.4.5 Uveitis
    • 4.4.6 Others
  • 4.5 Market Size & Forecast by Form (2020-2035)
    • 4.5.1 Liquid
    • 4.5.2 Solid
    • 4.5.3 Semi-Solid
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Intraocular Lenses
    • 4.6.2 Contact Lenses
    • 4.6.3 Ophthalmic Lasers
    • 4.6.4 Diagnostic Devices
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Ophthalmic Clinics
    • 4.7.3 Retail Pharmacies
    • 4.7.4 Online Pharmacies
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Anti-inflammatory
    • 4.8.2 Anti-infective
    • 4.8.3 Anti-glaucoma
    • 4.8.4 Anti-allergy
    • 4.8.5 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Vision Care
    • 4.9.2 Surgical Solutions
    • 4.9.3 Diagnostic Solutions
    • 4.9.4 Therapeutic Solutions
    • 4.9.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 Form
      • 5.2.1.6 Device
      • 5.2.1.7 End User
      • 5.2.1.8 Functionality
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 Form
      • 5.2.2.6 Device
      • 5.2.2.7 End User
      • 5.2.2.8 Functionality
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 Form
      • 5.2.3.6 Device
      • 5.2.3.7 End User
      • 5.2.3.8 Functionality
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 Form
      • 5.3.1.6 Device
      • 5.3.1.7 End User
      • 5.3.1.8 Functionality
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 Form
      • 5.3.2.6 Device
      • 5.3.2.7 End User
      • 5.3.2.8 Functionality
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 Form
      • 5.3.3.6 Device
      • 5.3.3.7 End User
      • 5.3.3.8 Functionality
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 Form
      • 5.4.1.6 Device
      • 5.4.1.7 End User
      • 5.4.1.8 Functionality
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 Form
      • 5.4.2.6 Device
      • 5.4.2.7 End User
      • 5.4.2.8 Functionality
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 Form
      • 5.4.3.6 Device
      • 5.4.3.7 End User
      • 5.4.3.8 Functionality
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 Form
      • 5.4.4.6 Device
      • 5.4.4.7 End User
      • 5.4.4.8 Functionality
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 Form
      • 5.4.5.6 Device
      • 5.4.5.7 End User
      • 5.4.5.8 Functionality
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 Form
      • 5.4.6.6 Device
      • 5.4.6.7 End User
      • 5.4.6.8 Functionality
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 Form
      • 5.4.7.6 Device
      • 5.4.7.7 End User
      • 5.4.7.8 Functionality
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 Form
      • 5.5.1.6 Device
      • 5.5.1.7 End User
      • 5.5.1.8 Functionality
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 Form
      • 5.5.2.6 Device
      • 5.5.2.7 End User
      • 5.5.2.8 Functionality
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 Form
      • 5.5.3.6 Device
      • 5.5.3.7 End User
      • 5.5.3.8 Functionality
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 Form
      • 5.5.4.6 Device
      • 5.5.4.7 End User
      • 5.5.4.8 Functionality
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 Form
      • 5.5.5.6 Device
      • 5.5.5.7 End User
      • 5.5.5.8 Functionality
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 Form
      • 5.5.6.6 Device
      • 5.5.6.7 End User
      • 5.5.6.8 Functionality
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 Form
      • 5.6.1.6 Device
      • 5.6.1.7 End User
      • 5.6.1.8 Functionality
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 Form
      • 5.6.2.6 Device
      • 5.6.2.7 End User
      • 5.6.2.8 Functionality
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 Form
      • 5.6.3.6 Device
      • 5.6.3.7 End User
      • 5.6.3.8 Functionality
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 Form
      • 5.6.4.6 Device
      • 5.6.4.7 End User
      • 5.6.4.8 Functionality
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 Form
      • 5.6.5.6 Device
      • 5.6.5.7 End User
      • 5.6.5.8 Functionality
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Novartis
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Roche
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Allergan
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bausch Health
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Alcon
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Johnson and Johnson
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bayer
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Pfizer
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Santen Pharmaceutical
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Regeneron Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sun Pharmaceutical
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Aerie Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Otsuka Pharmaceutical
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Teva Pharmaceutical
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 AbbVie
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Sanofi
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 GlaxoSmithKline
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 AstraZeneca
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Merck
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Eli Lilly
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us